Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab
Amgen Inc (NASDAQ: AMGN) Delayed: 354.04 -0.02 (0.01%)
Previous Close $354.06    52 Week High $176.85 
Open $357.40    52 Week Low $133.64 
Day High $358.17    P/E 53.32 
Day Low $351.96    EPS $6.64 
Volume 1,449,477